Re-Vana Therapeutics
Re-Vana Therapeutics is dedicated to advancing the quality of care for patients suffering from sight-threatening diseases through innovative sustained-release therapeutics. They develop and deliver in-clinic, photocrosslinked, biodegradable ocular biologics and small-molecule drugs with a focus on long-acting delivery systems.
Industries
Nr. of Employees
small (1-50)
Re-Vana Therapeutics
Products
Pre‑formed photocrosslinked biodegradable ocular implant (low-to-moderate release)
A pre‑formed, visible‑light photocrosslinked biodegradable implant engineered for sustained intraocular release up to approximately 6 months with adjustable release rates (example cited: ~0.1–0.625 µg/day) via polymer and crosslinking adjustments.
Pre‑formed high‑rate biodegradable ocular implant (for biologics)
A formulation variant of the pre‑formed implant optimized to deliver higher intraocular release rates (example cited: up to ~2 µg/day) suitable for potent biologics and biosimilars, with release governed by polymer, crosslinking and loading parameters.
Injectable in‑situ forming photo‑crosslinked ocular implant
An injectable gel system that undergoes phase inversion and visible‑light photo‑crosslinking after injection through a narrow‑gauge needle to form an implant in situ, supporting sustained release for 6–12 months and higher release rates (>4 µg/day) as described.
Pre‑formed photocrosslinked biodegradable ocular implant (low-to-moderate release)
A pre‑formed, visible‑light photocrosslinked biodegradable implant engineered for sustained intraocular release up to approximately 6 months with adjustable release rates (example cited: ~0.1–0.625 µg/day) via polymer and crosslinking adjustments.
Pre‑formed high‑rate biodegradable ocular implant (for biologics)
A formulation variant of the pre‑formed implant optimized to deliver higher intraocular release rates (example cited: up to ~2 µg/day) suitable for potent biologics and biosimilars, with release governed by polymer, crosslinking and loading parameters.
Injectable in‑situ forming photo‑crosslinked ocular implant
An injectable gel system that undergoes phase inversion and visible‑light photo‑crosslinking after injection through a narrow‑gauge needle to form an implant in situ, supporting sustained release for 6–12 months and higher release rates (>4 µg/day) as described.
Services
Collaborative studies to evaluate formulation approaches and preclinical performance of sustained‑release ocular therapeutics.
Strategic collaborations to apply photocrosslinked sustained‑release delivery platforms to partner assets and to support commercialization pathways.
Development of formulation variants for different APIs (biologics and small molecules) to achieve target release rates and durations through polymer and crosslinking modulation.
Collaborative studies to evaluate formulation approaches and preclinical performance of sustained‑release ocular therapeutics.
Strategic collaborations to apply photocrosslinked sustained‑release delivery platforms to partner assets and to support commercialization pathways.
Development of formulation variants for different APIs (biologics and small molecules) to achieve target release rates and durations through polymer and crosslinking modulation.
Expertise Areas
- Ocular drug delivery
- Extended‑release (long‑acting) therapeutics
- Formulation and preformulation development
- Drug‑device combination development
Key Technologies
- Visible‑light photocrosslinking
- Biodegradable polymer implants
- In‑situ forming injectable gels
- Phase inversion
News & Updates
Re-Vana has developed a novel disruptive photocrosslinked proprietary biodegradable sustained release drug delivery implant, EyeLief, which provides significant clinical benefits over current monthly intravitreal injections, offering a continuous release for effective AMD treatment over 4-6 months.
Re-Vana Therapeutics was recognized in the ‘Life and Health’ category of ‘INVENT 2015’ and received a prize, highlighting its innovative contributions.
Re-Vana planned to attend the retina and drug delivery focused OIS in Boston on August 12, 2017, and the Ophthalmology Futures Meeting in Lisbon on October 5, 2017.
Michael J. O’Rourke, CEO of Re-Vana Therapeutics, presented at the Ophthalmology Future Forum 2017 in Lisbon, Portugal.
Michael O’Rourke, CEO, was scheduled to present at the ISER Biennial International Society for Eye Research in Belfast, UK, on September 13, 2018, focusing on the development and commercialization of sustained release ocular drug delivery systems.
Queen’s University Belfast was ranked as the most entrepreneurial university in the UK, surpassing Oxford and Cambridge, according to a report published by Octopus Ventures.
Re-Vana has developed a novel disruptive photocrosslinked proprietary biodegradable sustained release drug delivery implant, EyeLief, which provides significant clinical benefits over current monthly intravitreal injections, offering a continuous release for effective AMD treatment over 4-6 months.
Re-Vana Therapeutics was recognized in the ‘Life and Health’ category of ‘INVENT 2015’ and received a prize, highlighting its innovative contributions.
Re-Vana planned to attend the retina and drug delivery focused OIS in Boston on August 12, 2017, and the Ophthalmology Futures Meeting in Lisbon on October 5, 2017.
Michael J. O’Rourke, CEO of Re-Vana Therapeutics, presented at the Ophthalmology Future Forum 2017 in Lisbon, Portugal.
Michael O’Rourke, CEO, was scheduled to present at the ISER Biennial International Society for Eye Research in Belfast, UK, on September 13, 2018, focusing on the development and commercialization of sustained release ocular drug delivery systems.
Queen’s University Belfast was ranked as the most entrepreneurial university in the UK, surpassing Oxford and Cambridge, according to a report published by Octopus Ventures.